Abstract
In silico methods have been used to identify five different classes of compounds as inhibitors of the essential Plasmodium falciparum enzyme lactate dehydrogenase (LDH). The molecules were assayed for in vitro antimalarial activity in both cell- and enzyme-based inhibition models. 5-Bromo-2-hydroxypyridine-3-carboxylic acid 19 is the most active with IC50 of 3.5 nM for chloroquine sensitive and 5 nM for resistant strains of Plasmodium falciparum, compared to 11 nM and 100 nM for the standard chloroquine. In LDH-enzyme inhibition assays the leading compounds are 5, 10, 18 and 19. Docking studies and the 3D-QSAR technique - CoRIA have been used to identify key binding elements between the molecules and residues in the LDH active site. A bifurcated salt bridge that associates the carboxylate group on the molecules with the guanidino group in the side chain of both Arg109 and Arg171 along with π-stack of the heterocycle with the pyridine ring of the cofactor NAD+, are the prime interactions. In silico ADME/toxicity studies also suggest these molecules have favorable pharmacokinetic and toxicity profiles.
Keywords: Antimalarial agents, CoRIA, docking, lactate dehydrogenase, Plasmodium falciparum, QSAR, Malaria
Anti-Infective Agents
Title: Molecular Modeling Studies, Synthesis and Biological Evaluation of Novel Plasmodium falciparum Lactate Dehydrogenase (pfLDH) Inhibitors
Volume: 10 Issue: 1
Author(s): Premlata K. Ambre, Raghuvir R. S. Pissurlenkar, Ashish S. Jagyasi, Ritesh A. Fule, Vijay Khedkar, Chandrashekar R. Barhate, Livia Vivas, Abhai K. Tripathi, David Sullivan, Richard Birkinshaw, R. Leo Brady, Krishna Iyer and Evans C. Coutinho
Affiliation:
Keywords: Antimalarial agents, CoRIA, docking, lactate dehydrogenase, Plasmodium falciparum, QSAR, Malaria
Abstract: In silico methods have been used to identify five different classes of compounds as inhibitors of the essential Plasmodium falciparum enzyme lactate dehydrogenase (LDH). The molecules were assayed for in vitro antimalarial activity in both cell- and enzyme-based inhibition models. 5-Bromo-2-hydroxypyridine-3-carboxylic acid 19 is the most active with IC50 of 3.5 nM for chloroquine sensitive and 5 nM for resistant strains of Plasmodium falciparum, compared to 11 nM and 100 nM for the standard chloroquine. In LDH-enzyme inhibition assays the leading compounds are 5, 10, 18 and 19. Docking studies and the 3D-QSAR technique - CoRIA have been used to identify key binding elements between the molecules and residues in the LDH active site. A bifurcated salt bridge that associates the carboxylate group on the molecules with the guanidino group in the side chain of both Arg109 and Arg171 along with π-stack of the heterocycle with the pyridine ring of the cofactor NAD+, are the prime interactions. In silico ADME/toxicity studies also suggest these molecules have favorable pharmacokinetic and toxicity profiles.
Export Options
About this article
Cite this article as:
K. Ambre Premlata, R. S. Pissurlenkar Raghuvir, S. Jagyasi Ashish, A. Fule Ritesh, Khedkar Vijay, R. Barhate Chandrashekar, Vivas Livia, K. Tripathi Abhai, Sullivan David, Birkinshaw Richard, Leo Brady R., Iyer Krishna and C. Coutinho Evans, Molecular Modeling Studies, Synthesis and Biological Evaluation of Novel Plasmodium falciparum Lactate Dehydrogenase (pfLDH) Inhibitors, Anti-Infective Agents 2012; 10 (1) . https://dx.doi.org/10.2174/2211362611201010055
DOI https://dx.doi.org/10.2174/2211362611201010055 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Components from Nature-Derived Drugs for the Treatment of Rheumatoid Arthritis
Current Drug Targets Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Microcirculatory Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitroxyl (HNO): A Possible Strategy for Fighting Cancer
Current Topics in Medicinal Chemistry 23Na Magnetic Resonance Imaging for the Determination of Myocardial Viability: The Status and the Challenges
Current Vascular Pharmacology Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?
Current Drug Targets Experimental Fracture Protocols in Assessments of Potential Agents for Osteoporotic Fracture Healing Using Rodent Models
Current Drug Targets Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Progress in Cationic Lipid-Mediated Gene Transfection: A Series of Bio- Inspired Lipids as an Example
Current Gene Therapy Selected Heterocyclic Compounds as Antioxidants. Synthesis and Biological Evaluation
Current Topics in Medicinal Chemistry Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking!
Current Pharmaceutical Design Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-Inflammatory Agents in Mouth-Rinses For Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery